Alx Oncology Holdings
$ 1.55
-1.27%
09 Jun - close price
- Market Cap 207,227,000 USD
- Current Price $ 1.55
- High / Low $ 1.62 / 1.52
- Stock P/E N/A
- Book Value 1.12
- EPS -1.49
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.74 %
- 52 Week High 2.66
- 52 Week Low 0.40
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
Analyst Target Price
$4.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-02-27 | 2025-11-07 | 2025-08-12 | 2025-05-08 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-10 |
| Reported EPS | -0.15 | -0.3697 | -0.41 | -0.44 | -0.4773 | -0.44 | -0.58 | -0.62 | -0.71 | -0.93 | -1.24 | -0.83 |
| Estimated EPS | -0.16 | -0.3525 | -0.37 | -0.31 | -0.309 | -0.39 | -0.66 | -0.7 | -0.71 | -0.84 | -0.89 | -0.86 |
| Surprise | 0.01 | -0.0172 | -0.04 | -0.13 | -0.1683 | -0.05 | 0.08 | 0.08 | 0 | -0.09 | -0.35 | 0.03 |
| Surprise Percentage | 6.25% | -4.8794% | -10.8108% | -41.9355% | -54.466% | -12.8205% | 12.1212% | 11.4286% | 0% | -10.7143% | -39.3258% | 3.4884% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALXO
2026-06-04 10:09:30
ALX Oncology Holdings (NASDAQ:ALXO) insiders who bought shares in the past year have seen their investment return positively despite a recent 15% stock dip, with their purchased shares now worth US$279.3k from an initial US$157.8k. While there has been modest insider selling recently, the overall trend over the last year shows more buying than selling, although at prices lower than the current trading price. Insiders currently own 1.2% of the company's stock, valued at US$2.9 million.
2026-06-04 05:09:30
The provided content is empty and does not contain any information about ALX Oncology, its drug programs, or any related readouts. Therefore, a summary cannot be generated.
2026-06-03 22:41:10
ALX Oncology Holdings Inc. (ALXO) is progressing two clinical programs: evorpacept for HER2-positive cancers and ALX2004, an EGFR ADC. Evorpacept has shown strong efficacy, and ALX2004 demonstrates promising safety and dose escalation, with both programs supported by robust funding. Key data and regulatory discussions are anticipated next year, particularly for the ASPEN-09 phase II trial which will refine the CD47 biomarker strategy.
2026-06-02 23:09:39
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. A webcast of the presentation will be available on the company's website and archived for 90 days. ALX Oncology is a clinical-stage biotechnology company focused on developing therapies for cancer, with lead candidate evorpacept and a second candidate, ALX2004, in clinical trials.
2026-06-02 08:41:10
ALX Oncology Holdings Inc. will be participating in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. The company, a clinical-stage biotechnology firm, is focused on developing novel therapies to treat cancer and extend patients' lives, with lead candidates evorpacept and ALX2004 currently in clinical trials. A webcast of the presentation will be available on ALX Oncology's investor relations website.
2026-06-01 11:39:41
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. The clinical-stage biotechnology company will discuss its pipeline of novel cancer therapies, including evorpacept and ALX2004. A webcast of the presentation will be available on the company's website and archived for 90 days.
